WallStreetZenWallStreetZen

NASDAQ: BLAC
Bellevue Life Sciences Acquisition Corp Stock

$10.75+0.00 (+0%)
Updated Jun 17, 2024
BLAC Price
$10.75
Fair Value Price
N/A
Market Cap
$60.45M
52 Week Low
$10.21
52 Week High
$11.60
P/E
537.5x
P/B
-14.03x
P/S
N/A
PEG
7.37x
Dividend Yield
N/A
Revenue
$0.00
Earnings
$233.05k
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-1.12
Operating Cash Flow
-$812k
Beta
0.01
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

BLAC Overview

Bellevue Life Sciences Acquisition Corp. focuses on effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. The company intends to acquire companies in the healthcare industry. Bellevue Life Sciences Acquisition Corp. was founded in 2020 and is based in Bellevue, Washington. Bellevue Life Sciences Acquisition Corp. operates as a subsidiary of Bellevue Global Life Sciences Investors LLC.

Zen Score

Industry Average (6)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BLAC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

BLAC ($10.75) is trading above its intrinsic value of $0.62, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BLAC is poor value based on its earnings relative to its share price (537.5x), compared to the US market average (31.44x)
P/E vs Market Valuation
BLAC is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more BLAC due diligence checks available for Premium users.

Be the first to know about important BLAC news, forecast changes, insider trades & much more!

BLAC News

Valuation

BLAC price to earnings (PE)

For valuing profitable companies with steady earnings
Company
537.5x
Industry
7.69x
Market
31.44x
BLAC is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
BLAC is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation

BLAC price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
-14.03x
Industry
-14.82x

BLAC price to earnings growth (PEG)

For valuing profitable companies with growth potential
BLAC is poor value relative... subscribe to Premium to read more.
PEG Value Valuation

BLAC's financial health

Profit margin

Revenue
$0.0
Net Income
-$60.4k
Profit Margin
0%
BLAC's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$37.3M
Liabilities
$4.8M
Debt to equity
-1.12
BLAC's short-term liabilities ($2.75M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BLAC's long-term liabilities ($2.07M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BLAC's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BLAC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$41.8k
Investing
-$120.0k
Financing
$150.0k
BLAC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

BLAC vs Shell Company Stocks

TickerMarket Cap1d %P/EP/B
BLAC$60.45M0.00%537.50x-14.03x
HAIA$60.91M0.00%40.36x-53.20x
TRON$61.24M0.00%-301.50x-5.36x
GBBK$61.42M+1.36%111.50x-32.28x
HUDA$58.82M-3.51%-4.23x-13.32x

Bellevue Life Sciences Acquisition Stock FAQ

What is Bellevue Life Sciences Acquisition's quote symbol?

(NASDAQ: BLAC) Bellevue Life Sciences Acquisition trades on the NASDAQ under the ticker symbol BLAC. Bellevue Life Sciences Acquisition stock quotes can also be displayed as NASDAQ: BLAC.

If you're new to stock investing, here's how to buy Bellevue Life Sciences Acquisition stock.

What is the 52 week high and low for Bellevue Life Sciences Acquisition (NASDAQ: BLAC)?

(NASDAQ: BLAC) Bellevue Life Sciences Acquisition's 52-week high was $11.60, and its 52-week low was $10.21. It is currently -7.33% from its 52-week high and 5.29% from its 52-week low.

How much is Bellevue Life Sciences Acquisition stock worth today?

(NASDAQ: BLAC) Bellevue Life Sciences Acquisition currently has 5,622,954 outstanding shares. With Bellevue Life Sciences Acquisition stock trading at $10.75 per share, the total value of Bellevue Life Sciences Acquisition stock (market capitalization) is $60.45M.

Bellevue Life Sciences Acquisition stock was originally listed at a price of $10.16 in Feb 10, 2023. If you had invested in Bellevue Life Sciences Acquisition stock at $10.16, your return over the last 1 years would have been 5.81%, for an annualized return of 5.81% (not including any dividends or dividend reinvestments).

How much is Bellevue Life Sciences Acquisition's stock price per share?

(NASDAQ: BLAC) Bellevue Life Sciences Acquisition stock price per share is $10.75 today (as of Jun 17, 2024).

What is Bellevue Life Sciences Acquisition's Market Cap?

(NASDAQ: BLAC) Bellevue Life Sciences Acquisition's market cap is $60.45M, as of Jun 20, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Bellevue Life Sciences Acquisition's market cap is calculated by multiplying BLAC's current stock price of $10.75 by BLAC's total outstanding shares of 5,622,954.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.